FDA Breakthrough Device Designation

Breakthrough Device Designation is a voluntary FDA program that expedites the development and prioritizes the review of certain medical devices and device-led combination products. Created by Section 3051 of the 21st Century Cures Act, signed into law on December 13, 2016, and codified at Section 515B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §360e-3), it replaced and expanded FDA’s earlier, non-statutory Expedited Access Pathway for devices.

Last verified August 25, 2026 against the statutory text at 21 U.S.C. §360e-3 and FDA’s Breakthrough Devices Program guidance.

Designation Criteria

Section 515B(b) sets out two conjunctive requirements. A device must satisfy the first, plus at least one sub-paragraph of the second:

1. Serious-condition requirement

The device must provide “more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions” — the same threshold language used across FDA’s expedited programs for drugs and biologics, applied here to devices.

2. At least one of the following

• The device represents a breakthrough technology.
• No approved or cleared alternative exists for the disease or condition.
• The device offers significant advantages over existing approved or cleared alternatives, including the potential to reduce or eliminate the need for hospitalization, improve patients’ quality of life, facilitate patients’ ability to manage their own care (e.g., at home), or establish long-term clinical efficiencies.
• The device’s availability is otherwise in the best interest of patients.

FDA guidance also extends eligibility to certain devices addressing health or healthcare disparities, and to certain non-addictive products intended to treat pain or opioid use disorder, applying the same underlying two-part test.

What the Designation Grants

A designated device is eligible for FDA’s prioritized review and expedited development support, delivered through several concrete mechanisms specified in the statute:

• A dedicated review team, including a team leader with relevant subject-matter expertise, assigned for the life of the development program.
• Senior-manager engagement from FDA to help ensure efficient development and review.
• Interactive and timely communication with the sponsor, including the option of more frequent, structured meetings (“sprint discussions”) to resolve specific development or evidentiary questions quickly.
• Priority review of the eventual marketing submission (510(k), De Novo request, or PMA), ahead of non-designated submissions in FDA’s review queue.
• The option of a written, FDA-agreed Data Development Plan and clinical-protocol agreements that FDA can only later modify by mutual consent or a documented, substantial scientific disagreement.

None of this substitutes for the underlying marketing pathway’s evidentiary standard: a Breakthrough Device still must clear 510(k) substantial-equivalence review, receive a De Novo classification, or win PMA approval on the same safety-and-effectiveness basis as any other device in that pathway.

Requesting and Keeping the Designation

A sponsor may request designation at any point before submitting a premarket approval application, 510(k), or De Novo request — there is no fixed “must request by” development milestone as there is for some drug programs. FDA must respond in writing within 60 calendar days of receiving a complete request. Designation is not automatically lost if a competing device is later cleared or approved: the statute specifically bars FDA from withdrawing a designation for that reason alone, though FDA can withdraw it if the device no longer meets the qualifying criteria on the evidence.

Breakthrough Device vs. Other FDA Pathways

	Breakthrough Device Designation	De Novo Classification	510(k)	Breakthrough Therapy (drugs)
What it is	An expedited-review status layered onto an existing device pathway	A pathway that creates a new device classification when no predicate exists	A pathway showing substantial equivalence to an existing predicate device	The drug-side program with a similar name and structure, but a separate statutory provision (Section 506(a))
Confers marketing authorization?	No — still requires 510(k), De Novo, or PMA	Yes, on grant	Yes, on clearance	No — still requires NDA/BLA approval
Statutory basis	Section 515B, FD&C Act (21 U.S.C. §360e-3)	Section 513(f)(2), FD&C Act (21 U.S.C. §360c(f)(2))	Section 510(k), FD&C Act	Section 506(a), FD&C Act
Response clock	60 days to decide the designation request	120 days to decide the classification request	90 days (MDUFA goal) to clear or not	60 days to decide the designation request

See the 510(k) vs. PMA comparison and the De Novo Classification entry for how a Breakthrough-designated device’s actual marketing pathway works once the underlying evidence is in hand.

Why This Matters for Research Administration

For research administrators and clinical trial operations staff, a Breakthrough-designated device program often means a compressed, less predictable protocol-amendment cadence: the sponsor’s more frequent FDA interactions can generate design changes or expanded-access requests on short notice relative to a standard development program. Institutions supporting these trials should expect earlier and more iterative IRB review cycles as protocol elements are refined in response to FDA sprint discussions, and should not assume the device’s ultimate safety or efficacy bar has been lowered — designation changes FDA’s engagement, not the standard the marketing application must meet.

Frequently Asked Questions

Does Breakthrough Device Designation mean a device is FDA-approved?

No. It is a development- and review-acceleration status. The device still requires 510(k) clearance, De Novo classification, or PMA approval before it can be legally marketed.

How is Breakthrough Device Designation different from Breakthrough Therapy Designation?

Breakthrough Device Designation applies to medical devices under Section 515B; Breakthrough Therapy Designation applies to drugs and biologics under the separate Section 506(a). The two programs share a name and a similar expedited-development logic but rest on different statutory provisions with different criteria.

Can FDA revoke a Breakthrough Device Designation if a competitor gets cleared first?

No. The statute specifically prohibits FDA from withdrawing a designation solely because another device with an approved or cleared alternative later reaches the market.

How long does FDA take to decide a designation request?

FDA must respond within 60 calendar days of receiving the request.

References

• 21 U.S.C. §360e-3 (FD&C Act Section 515B), via GovInfo, U.S. Code.
• 21st Century Cures Act, Pub. L. No. 114-255, §3051 (2016).
• U.S. Food and Drug Administration, “Breakthrough Devices Program” guidance.
• Health Affairs Forefront, “FDA Breakthrough Device Designation: Clinical Evidence and Medicare Payment Policies.”